Biosafety model of adenovirus infection: Effects of bacterial proteases for infection of human cells in vitro

To determine the antiviral activity of various biologically active compounds, the model of adenovirus infection on the basis of cell cultures of human HEK293A and recombinant adenovirus Ad-EGFP, expressing green fluorescent protein EGFP. Adenoviruses have a capsid size of 70-90 nm and are able to infect dividing and nondividing cells in vitro and in vivo. Recombinant adenoviruses are the replicative defect in the cells of humans and animals. The developed model allowed us to determine the effect of bacterial proteases in the infected cell cultures with adenovirus. This model can also be used for screening drugs with potential protivivovirusnoy activity

Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients

Background Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown. Methods Patients who were hospitalized for acute medical illnesses were randomly assigned to receive subcutaneous enoxaparin (at a dose of 40 mg once daily) for 10±4 days plus oral betrixaban placebo for 35 to 42 days or subcutaneous enoxaparin placebo for 10±4 days plus oral betrixaban (at a dose of 80 mg once daily) for 35 to 42 days. We performed sequential analyses in three prespecified, progressively inclusive cohorts: patients with an elevated d-dimer level (cohort 1), patients with an elevated d-dimer level or an age of at least 75 years (cohort 2), and all the enrolled patients (overall population cohort). The statistical analysis plan specified that if the between-group difference in any analysis in this sequence was not significant, the other analyses would be considered exploratory. The primary efficacy outcome was a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism. The principal safety outcome was major bleeding. Results A total of 7513 patients underwent randomization. In cohort 1, the primary efficacy outcome occurred in 6.9% of patients receiving betrixaban and 8.5% receiving enoxaparin (relative risk in the betrixaban group, 0.81; 95% confidence interval [CI], 0.65 to 1.00; P=0.054). The rates were 5.6% and 7.1%, respectively (relative risk, 0.80; 95% CI, 0.66 to 0.98; P=0.03) in cohort 2 and 5.3% and 7.0% (relative risk, 0.76; 95% CI, 0.63 to 0.92; P=0.006) in the overall population. (The last two analyses were considered to be exploratory owing to the result in cohort 1.) In the overall population, major bleeding occurred in 0.7% of the betrixaban group and 0.6% of the enoxaparin group (relative risk, 1.19; 95% CI, 0.67 to 2.12; P=0.55). Conclusions Among acutely ill medical patients with an elevated d-dimer level, there was no significant difference between extended-duration betrixaban and a standard regimen of enoxaparin in the prespecified primary efficacy outcome. However, prespecified exploratory analyses provided evidence suggesting a benefit for betrixaban in the two larger cohorts. (Funded by Portola Pharmaceuticals; APEX ClinicalTrials.gov number, NCT01583218. opens in new tab.

Biosafety model of adenovirus infection: Effects of bacterial proteases for infection of human cells in vitro

To determine the antiviral activity of various biologically active compounds, the model of adenovirus infection on the basis of cell cultures of human HEK293A and recombinant adenovirus Ad-EGFP, expressing green fluorescent protein EGFP. Adenoviruses have a capsid size of 70-90 nm and are able to infect dividing and nondividing cells in vitro and in vivo. Recombinant adenoviruses are the replicative defect in the cells of humans and animals. The developed model allowed us to determine the effect of bacterial proteases in the infected cell cultures with adenovirus. This model can also be used for screening drugs with potential protivivovirusnoy activity

Biosafety model of adenovirus infection: Effects of bacterial proteases for infection of human cells in vitro

To determine the antiviral activity of various biologically active compounds, the model of adenovirus infection on the basis of cell cultures of human HEK293A and recombinant adenovirus Ad-EGFP, expressing green fluorescent protein EGFP. Adenoviruses have a capsid size of 70-90 nm and are able to infect dividing and nondividing cells in vitro and in vivo. Recombinant adenoviruses are the replicative defect in the cells of humans and animals. The developed model allowed us to determine the effect of bacterial proteases in the infected cell cultures with adenovirus. This model can also be used for screening drugs with potential protivivovirusnoy activity

Pleuropulmonary blastoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations

Pleuropulmonary blastoma (PPB) is a rare cancer occurring mainly during early childhood and often associated with germline DICER1 mutations. It is classified by the macroscopic appearance into three interrelated clinico-pathologic entities on a developmental continuum. Complete tumor resection is a main prognostic factor and can be performed at diagnosis or after neoadjuvant treatment that includes chemotherapy and in some cases radiotherapy. Optimal modalities of neo- or adjuvant treatments can be challenging taking into account potential long-term toxicities in this young population. This paper presents the recommendations for diagnosis and treatment of children and adolescents with PPB elaborated by the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) within the European Union-funded project PARTNER (Paediatric Rare Tumours Network - European Registry)